Novartis International AG — Ethics Grade C

Novartis International AG receives an overall ethics grade of C (48/100) on CancelCo's corporate accountability database. Sector: Healthcare. Market cap: Large Cap.

Category scores

• labor: 60
• privacy: 60
• consumer: 40
• environment: 65
• humanRights: 55

Documented incidents (3)

• Greece Bribery Settlement (high, 2020) — Novartis paid $347 million to the US DOJ to settle charges of bribing healthcare providers in Greece to increase prescriptions of its drugs.
• Zolgensma Data Inaccuracies (high, 2019) — The FDA revealed that Novartis submitted manipulated data during the testing of its $2.1 million gene therapy, Zolgensma.
• Exforge Generic Blocking (medium, 2023) — Settled a lawsuit for $245 million over allegations of illegally delaying the entry of generic versions of the blood pressure drug Exforge.

Documented good deeds

• Malaria Access Program — Provided over 1 billion courses of antimalarial treatment to patients in endemic countries at no-profit prices.

Ethical alternatives

• Novo Nordisk — Stronger focus on social responsibility and insulin access programs.